Immunotherapy has brought promising breakthroughs to several types of cancer. Cervical cancer has a relatively large number of mutations (gene changes), which may make it more sensitive to immunotherapy drugs and may apply immunotherapy to cervical cancer.
A number of clinical trials are in full swing, and the researchers recently summarized a phase II trial of single drug nivolumab (Opdivo) for recurrent cervical cancer. Among the 24 patients: 19 had cervical cancer, 5 had vaginal cancer, and 26% of cervical cancer patients responded to the drug, which is an encouraging result.
Researchers will continue to improve the single-drug program through further trials, but are also pursuing another approach: combination trials. Studies using single-agent immunotherapy with drugs such as pembrolizumab (Keytruda) or nivolumab show that 15% -25% of patients are active, but the remaining patients are inactive, and there is much room for improvement. For this reason, the researchers are more focused on combined trials of cervical cancer.
Et eksperiment pågår for å parre immunterapi medikamentet atezolizumab (Tecentriq) med det antiangiogene middelet bevacizumab, som forhindrer kreftceller i å danne nye blodkar som trenger å vokse. Bevacizumab er et aktivt medikament mot livmorhalskreft, og det er prekliniske data om at bevacizumab kan forbedre effekten av immunterapi. Derfor er dette en spennende kombinasjon av livmorhalskreft, og vi venter spent på resultatene av denne studien.
In another clinical trial, researchers are studying how two immunotherapy drugs, durvalumab (IMFINZI) and tremelimumab, can be combined with radiation therapy to see if radiation can enhance the immune response.
Stadig mer livmorhalskreftimmunoterapi-forskning har gitt livmorhalskreftpasienter stort håp, og vi ser frem til bedre behandlingseffekter.
